STOCK TITAN
  1. Home
  2. News
  3. OYST

Oyster Point Pharma to Participate in the LifeSci Partners Genetic Medicines Summit

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

PRINCETON, N.J., June 21, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies to treat ophthalmic diseases, today announced that the Company will participate virtually in the LifeSci Partners Genetic Medicines Summit on Tuesday, June 22, 2021, at 2:00 p.m. ET.

To access the live webcast, please visit the “Investors and News” section of the Oyster Point Pharma website at https://investors.oysterpointrx.com/.

About Oyster Point Pharma
Oyster Point Pharma is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies to treat ophthalmic diseases.

Investor Contact: 
Tim McCarthy 
LifeSci Advisors, LLC 
(212) 915-2564 
investors@oysterpointrx.com

Media Contact: 
Sheryl Seapy
Real Chemistry 
(213) 262-9390 
sseapy@realchemistry.com


Stock OYST logo
OYST

NASDAQ:OYST

OYST Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

OYST Latest News

Dec 2, 2022
Oyster Point Pharma, Inc., Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nov 10, 2022
Oyster Point Pharma Reports Third Quarter 2022 Financial Results and Recent Business Highlights
Nov 7, 2022
Oyster Point Pharma, a Leading Ophthalmology-Focused Biopharmaceutical Company, to be Acquired by Viatris
Nov 2, 2022
Oyster Point Pharma To Report Third Quarter 2022 Financial Results On November 10, 2022
Nov 2, 2022
Oyster Point Pharma, Inc., Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

OYST Stock Data

299.85M
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link

About OYST

Oyster Point Pharma is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases. Oyster Point Pharma's lead product candidate, OC-01 (varenicline) nasal spray, a highly selective cholinergic agonist, is being developed as a nasal spray to treat the signs and symptoms of dry eye disease. In pre-clinical and clinical studies, OC-01 (varenicline) nasal spray was shown to have a novel mechanism of action via activation of the trigeminal parasympathetic pathway to stimulate the glands and cells responsible for natural tear film production, known as the lacrimal functional unit.